000169051 001__ 169051
000169051 005__ 20240229133637.0
000169051 0247_ $$2doi$$a10.1210/clinem/dgab391
000169051 0247_ $$2pmid$$apmid:34061963
000169051 0247_ $$2ISSN$$a0021-972X
000169051 0247_ $$2ISSN$$a0368-1610
000169051 0247_ $$2ISSN$$a1945-7197
000169051 0247_ $$2ISSN$$a2578-7241
000169051 0247_ $$2altmetric$$aaltmetric:106862960
000169051 037__ $$aDKFZ-2021-01209
000169051 041__ $$aEnglish
000169051 082__ $$a610
000169051 1001_ $$00000-0002-2254-8152$$aCao, Junguo$$b0
000169051 245__ $$aInsulin-like growth factor 2 mRNA-binding protein 2 - a potential link between type 2 diabetes mellitus and cancer.
000169051 260__ $$aOxford$$bOxford University Press$$c2021
000169051 3367_ $$2DRIVER$$aarticle
000169051 3367_ $$2DataCite$$aOutput Types/Journal article
000169051 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1634895124_5773$$xReview Article
000169051 3367_ $$2BibTeX$$aARTICLE
000169051 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169051 3367_ $$00$$2EndNote$$aJournal Article
000169051 500__ $$a2021 Sep 27;106(10):2807-2818
000169051 520__ $$aType 2 diabetes mellitus (T2DM) and cancer share a variety of risk factors and pathophysiological features. It is becoming increasingly accepted that the two diseases are related, and that T2DM increases the risk of certain malignancies. This review summarizes recent advancements in the elucidation of functions of insulin-like growth factor 2 (IGF-2) mRNA-binding protein 2 (IGF2BP2) in T2DM and cancer.A PubMed review of the literature was conducted, and search terms included: IGF2BP2, IMP2, or p62 in combination with cancer or T2DM. Additional sources were identified through manual searches of reference lists.The increased risk of multiple malignancies and cancer-associated mortality in patients with T2DM is believed to be driven by insulin resistance, hyperinsulinemia, hyperglycemia, chronic inflammation, and dysregulation of adipokines and sex hormones. Furthermore, IGF-2 is oncogenic, and its loss-of-function splice variant is protective against T2DM, which highlights the pivotal role of this growth factor in the pathogenesis of these two diseases. IGF-2 mRNA-binding proteins, particularly IGF2BP2, are also involved in T2DM and cancer, and single nucleotide polymorphisms of IGF2BP2 are associated with both diseases. Deletion of the IGF2BP2 gene in mice improves their glucose tolerance and insulin sensitivity and mice with transgenic p62, a splice variant of IGF2BP2, are prone to diet-induced fatty liver disease and hepatocellular carcinoma, suggesting the biological significance of IGF2BP2 in T2DM and cancer.Accumulating evidence revealed that IGF2BP2 mediates the pathogenesis of T2DM and cancer by regulating glucose metabolism, insulin sensitivity, and tumorigenesis. This review provides insight into the potential involvement of this RNA binding protein in the link between T2DM and cancer.
000169051 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000169051 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169051 650_7 $$2Other$$aIGF-2 mRNA-binding protein 2
000169051 650_7 $$2Other$$acancer
000169051 650_7 $$2Other$$ainflammation
000169051 650_7 $$2Other$$ametabolism
000169051 650_7 $$2Other$$atype 2 diabetes mellitus
000169051 7001_ $$aYan, Weijia$$b1
000169051 7001_ $$0P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3$$aMa, Xiujian$$b2$$udkfz
000169051 7001_ $$aHuang, Haiyan$$b3
000169051 7001_ $$aYan, Hong$$b4
000169051 773__ $$0PERI:(DE-600)2026217-6$$a10.1210/clinem/dgab391$$gp. dgab391$$n10$$p2807-2818$$tThe journal of clinical endocrinology & metabolism$$v106$$x1945-7197$$y2021
000169051 909CO $$ooai:inrepo02.dkfz.de:169051$$pVDB
000169051 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000169051 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000169051 9130_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000169051 9141_ $$y2021
000169051 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-30$$wger
000169051 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN ENDOCR METAB : 2019$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-30
000169051 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ CLIN ENDOCR METAB : 2019$$d2021-01-30
000169051 9201_ $$0I:(DE-He78)A240-20160331$$kA240$$lA240 Molekulare Neurogenetik$$x0
000169051 980__ $$ajournal
000169051 980__ $$aVDB
000169051 980__ $$aI:(DE-He78)A240-20160331
000169051 980__ $$aUNRESTRICTED